首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation.
【24h】

Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation.

机译:骨髓移植物抗宿主病:MHC不匹配的造血干细胞移植后,造血生态位的早期破坏。

获取原文
获取原文并翻译 | 示例
       

摘要

Disrupted hematopoiesis and delayed immune reconstitution are life-threatening complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although graft-versus-host disease (GVHD) is a major risk factor for the bone marrow (BM) insufficiency, how GVHD impairs BM hematopoiesis has been largely unknown. We hypothesized that BM stromal niche could be a target of GVHD. In major histocompatibility complex (MHC)-mismatched murine models of GVHD, we have demonstrated the early destruction of osteoblasts that especially affected B-cell lineages. The defective B lymphopoiesis was due to the impaired ability of BM stroma and osteoblasts to support the hematopoiesis, as evidenced by the failure of GVHD-affected BM to reconstitute the hematopoietic cells. The administration of anti-CD4 monoclonal antibody (mAb) ameliorated these effects and improved B lymphopoiesis while preserving graft-versus-tumor effects. Genetic ablation of Fas-Fas ligand signaling also partially restored B lymphopoiesis. Our present study provided evidence of BM GVHD, with the identification of osteoblasts as the main target for GVHD in BM. Moreover, our data showed the potential for mAb therapies to enhance immune reconstitution in vivo for patients undergoing allo-HSCT.
机译:血细胞生成中断和免疫重建延迟是异基因造血干细胞移植(allo-HSCT)的危及生命的并发症。尽管移植物抗宿主病(GVHD)是骨髓(BM)功能不全的主要危险因素,但很大程度上尚不清楚GVHD如何损害BM造血功能。我们假设BM基质生态位可能是GVHD的目标。在GVHD的主要组织相容性复合体(MHC)不匹配的小鼠模型中,我们证明了成骨细胞的早期破坏,尤其是影响B细胞谱系的成骨细胞。有缺陷的B淋巴细胞生成是由于BM基质和成骨细胞支持造血功能受损,这是受GVHD影响的BM不能重建造血细胞所证明的。抗CD4单克隆抗体(mAb)的使用改善了这些作用并改善了B淋巴细胞生成,同时保留了移植物抗肿瘤作用。 Fas-Fas配体信号转导的遗传消融也部分恢复了B淋巴细胞生成。我们目前的研究提供了BM GVHD的证据,鉴定成骨细胞是BM GVHD的主要靶标。此外,我们的数据显示,对于接受allo-HSCT的患者,mAb治疗具有增强体内免疫重建的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号